Plus Therapeutics Inc. (PSTV)
NASDAQ: PSTV
· Real-Time Price · USD
0.63
0.09 (16.19%)
At close: Aug 15, 2025, 3:59 PM
0.57
-9.98%
After-hours: Aug 15, 2025, 07:58 PM EDT
Plus Therapeutics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 1.06M | n/a | n/a | 1.28M | 1.68M | 1.31M | 1.24M | 1.85M | n/a | 224K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 181K | n/a | 232K | 202K | 186K | 182K | 188K | 188K | n/a | 287K | n/a | 165K | 137K | 117K | 18K | 94K | 89K |
Gross Profit | 878K | n/a | n/a | -1.49M | 1.49M | 1.13M | 1.05M | 1.67M | n/a | -63K | n/a | -165K | -137K | -117K | -18K | -94K | -89K |
Operating Income | -3.54M | -3.9M | -3.8M | -3.7M | -3.3M | -3.86M | -3.25M | -1.49M | -4.72M | -5.57M | -5.09M | -5.12M | -3.93M | -3.94M | -3.5M | -2.58M | -2.48M |
Interest Income | 1K | 54K | 80K | 67K | 72K | 110K | 119K | 120K | 51K | 73K | 48K | 19K | 7K | 6K | 5K | 4K | 4K |
Pretax Income | -17.4M | -3.9M | -2.87M | -2.94M | -3.26M | -3.81M | -3.22M | -1.48M | -4.8M | -5.66M | -5.22M | -5.28M | -4.12M | -4.16M | -3.72M | -2.8M | -2.72M |
Net Income | -17.4M | -3.9M | -2.87M | -2.94M | -3.26M | -3.81M | -3.22M | -1.48M | -4.8M | -5.66M | -5.22M | -5.28M | -4.12M | -4.16M | -3.72M | -2.8M | -2.72M |
Selling & General & Admin | 2.66M | 3.13M | 2.4M | 2.2M | 2.21M | 2.38M | 2M | 1.92M | 2.25M | 3.58M | 2.22M | 2.29M | 2.14M | 2.04M | 1.99M | 1.47M | 1.35M |
Research & Development | 1.76M | 2.19M | 2.86M | 2.77M | 2.76M | 2.79M | 2.49M | 1.42M | 2.98M | 2.14M | 2.94M | 2.83M | 1.78M | 1.85M | 1.49M | 1.11M | 1.13M |
Other Expenses | n/a | -1.41M | -1.46M | -1.28M | n/a | n/a | n/a | n/a | n/a | 73K | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 4.41M | 3.9M | 2.4M | 2.2M | 4.79M | 4.99M | 4.49M | 3.34M | 5.23M | 5.8M | 5.17M | 5.12M | 3.93M | 3.89M | 3.48M | 2.58M | 2.48M |
Interest Expense | 3.76M | 57K | 61K | 3.57M | 34K | 62K | 87K | 112K | 134K | 159K | 173K | 181K | 198K | 224K | 232K | 229K | 247K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.59M | 3.9M | 3.8M | 3.7M | 4.98M | 5.17M | 4.49M | 3.34M | 5.23M | 5.8M | 5.17M | 5.12M | 3.93M | 3.94M | 3.5M | 2.58M | 2.48M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 14.57M | 7.87M | 7.86M | 6.5M | 4.32M | 4.5M | 3.23M | 2.51M | 2.32M | 26.26M | 1.83M | 1.48M | 1.43M | 12.09M | 884.28K | 753.12K | 551.19K |
Shares Outstanding (Diluted) | 14.57M | 5.9M | 7.86M | 10.74M | 4.32M | 4.5M | 3.23M | 2.51M | 2.32M | 26.26M | 1.83M | 1.48M | 1.43M | 12.09M | 884.28K | 753.12K | 551.19K |
EPS (Basic) | -1.19 | -0.1 | -0.37 | -0.45 | -0.75 | -0.84 | -1 | -0.59 | -2.07 | -2.56 | -2.85 | -3.56 | -2.85 | -4.05 | -4.21 | -3.72 | -4.93 |
EPS (Diluted) | -1.19 | -0.5 | -0.37 | -0.71 | -0.75 | -0.84 | -1 | -0.59 | -2.07 | -2.56 | -2.85 | -3.56 | -2.85 | -4.03 | -4.21 | -3.72 | -4.93 |
EBITDA | -13.46M | -3.74M | -2.58M | 834K | -3.04M | -3.68M | -2.94M | -1.18M | -4.48M | -5.21M | -4.92M | -4.94M | -3.78M | -3.81M | -3.4M | -2.48M | -2.38M |
EBIT | -13.64M | -3.9M | -2.81M | 632K | -3.23M | -3.75M | -3.13M | -1.37M | -4.67M | -5.5M | -5.05M | -5.1M | -3.92M | -3.93M | -3.49M | -2.57M | -2.47M |
Depreciation & Amortization | 181K | 103K | 232K | 202K | 186K | 65K | 188K | 188K | 187K | 159K | 224K | 165K | 172K | 129K | 87K | 91K | 88K |